However, detection of a distinct mutation, aberration or translocation of the tumor cells and the evidence of a specific immunoreactivity, as determined by the expression of programmed death-receptor 1 (PD-1) and its ligand (PD-L1) on tumor cell surface (PD-L1) or patients’ T-cells (PD-1), are crucial to predict therapeutic effectiveness. The gene discussed is CD274; the disease is neoplasm.